188 related articles for article (PubMed ID: 36056210)
41. Prevalence and prognostic significance of IKZF1 deletion in paediatric acute lymphoblastic leukemia: A systematic review and meta-analysis.
Srinivasan S; Ramanathan S; Kumar S; Peyam S; Radhakrishnan V
Ann Hematol; 2023 Aug; 102(8):2165-2179. PubMed ID: 37154889
[TBL] [Abstract][Full Text] [Related]
42. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
[TBL] [Abstract][Full Text] [Related]
43. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G
Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361
[TBL] [Abstract][Full Text] [Related]
44. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic hematopoietic stem cell transplantation improves the prognosis of p16-deleted adult patients with acute lymphoblastic leukemia.
Wang Y; Chen G; Cao R; Li J; He L; Guo X; Liang J; Shi P; Zhou Y; Xu B
Pharmacogenomics; 2017 Jan; 18(1):77-84. PubMed ID: 27967319
[TBL] [Abstract][Full Text] [Related]
46. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
47. Loss-of-function but not dominant-negative intragenic
Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
[TBL] [Abstract][Full Text] [Related]
48. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract][Full Text] [Related]
49. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
Bai L; Cheng YF; Lu AD; Suo P; Wang Y; Zuo YX; Yan CH; Wu J; Jia YP; Sun YQ; Chen YH; Chen H; Liu KY; Han W; Xu LP; Wang JB; Tang XF; Chen HR; Zhang LP; Huang XJ
Leuk Res; 2020 Apr; 91():106333. PubMed ID: 32109757
[TBL] [Abstract][Full Text] [Related]
50. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
51. Impact of
Felice MS; Rubio PL; Digiorge J; Barreda Frank M; Martínez CS; Guitter MR; Sajaroff EO; Sánchez La Rosa CG; Pennella CL; Peruzzo LB; Deu MA; Alfaro EM; Guardia MC; Gutierrez G; Fernández Barbieri MA; Recondo E; Vides Herrera MS; Livio V; Arnaiz C; Romero C; Alonso CN; Rossi JG;
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805054
[TBL] [Abstract][Full Text] [Related]
52. Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
Lin S; Liao N; Li X; Yang L; He YY; Tang YL; Wan WQ; Jia W; Zhang YJ; Kong Q; Long X; Lan X; Ling YY; Lin D; Zhang XL; Wen C; Li CK; Xu HG
Eur J Haematol; 2024 Jun; ():. PubMed ID: 38847134
[TBL] [Abstract][Full Text] [Related]
53. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia".
Palmi C; Lana T; Silvestri D; Savino A; Kronnie GT; Conter V; Basso G; Biondi A; Valsecchi MG; Cazzaniga G
Haematologica; 2013 Dec; 98(12):e164-5. PubMed ID: 24323991
[No Abstract] [Full Text] [Related]
54. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
[TBL] [Abstract][Full Text] [Related]
55. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia.
Bachanova V; Sandhu K; Yohe S; Cao Q; Burke MJ; Verneris MR; Weisdorf D
Blood; 2011 May; 117(19):5261-3. PubMed ID: 21403127
[TBL] [Abstract][Full Text] [Related]
57. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
[TBL] [Abstract][Full Text] [Related]
58. Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.
Churchman ML; Qian M; Te Kronnie G; Zhang R; Yang W; Zhang H; Lana T; Tedrick P; Baskin R; Verbist K; Peters JL; Devidas M; Larsen E; Moore IM; Gu Z; Qu C; Yoshihara H; Porter SN; Pruett-Miller SM; Wu G; Raetz E; Martin PL; Bowman WP; Winick N; Mardis E; Fulton R; Stanulla M; Evans WE; Relling MV; Pui CH; Hunger SP; Loh ML; Handgretinger R; Nichols KE; Yang JJ; Mullighan CG
Cancer Cell; 2018 May; 33(5):937-948.e8. PubMed ID: 29681510
[TBL] [Abstract][Full Text] [Related]
59. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
Medeiros BC
N Engl J Med; 2009 Apr; 360(17):1787; author reply 1787-8. PubMed ID: 19387020
[No Abstract] [Full Text] [Related]
60. Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG).
Asai D; Imamura T; Yamashita Y; Suenobu S; Moriya-Saito A; Hasegawa D; Deguchi T; Hashii Y; Endo M; Hatakeyama N; Kawasaki H; Hori H; Horibe K; Yumura-Yagi K; Hara J; Watanabe A; Kikuta A; Oda M; Sato A;
Cancer Med; 2014 Jun; 3(3):623-31. PubMed ID: 24578304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
